Highest-materiality recent filing
CME Group announces pricing changes via Special Executive Report No. 9799
Pricing changes communicated to clients on Aug 11, 2026 via Special Executive Report No. 9799.
CME Group reports Q2 2026 results; press release not provided in filing text
Filing states a press release was attached as Exhibit 99.1 reporting financial results for quarter ended June 30, 2026.
Terrence A. Duffy will become Executive Chairman effective March 1, 2027 (or later when 2026 10-K is filed); he remains CEO until then.
Item 4 to eliminate Class B-1 right to elect three directors failed (27.84% B-1 FOR; 80.27% combined FOR but needed majority of outstanding B-1).
CME Group adjourns four proposals due to Class B quorum shortfall; elects all director nominees
Class B-1 through B-4 failed quorum (33.3% required); only 24-33% present. Proposals 4-8 adjourned to June 9, 2026 virtual meeting.
CME Group subsidiary amends $7B clearing house credit facility
Amendment No. 11 to 364-day multi-currency revolving secured credit facility, dated April 22, 2026.
CME Group files 8-K for Q1 2026 earnings; press release exhibit not provided in input
Furnished quarterly financial results for quarter ended March 31, 2026.
Q4 2025 revenue $1.8B (+20% YoY), record full-year revenue $7.1B (+35%).
CME Group Announces Pricing Changes via Special Executive Report 9676
On February 2, 2026, CME Group communicated pricing changes to clients in Special Executive Report 9676.
CME Group Q3 2025 earnings reported; press release not provided
Exhibit 99.1 press release text missing; specific financial figures unavailable.
CME Group CAO Jack Tobin to retire; will stay through Oct 30, 2026
Jack Tobin, Managing Director and Chief Accounting Officer, notified retirement on Sept 9, 2025.
CME Group wins unanimous jury verdict in Class B shareholder lawsuit
Jury returned unanimous verdict on July 25, 2025 in favor of CME Group and CBOT.
CME Group Inc. reports financial results for quarter ended June 30, 2025
CME Group issued a press release on July 23, 2025 reporting its financial results for the quarter ended June 30, 2025.
CME Group 2025 annual meeting elects 14 directors, ratifies auditor, approves say-on-pay
All 14 equity directors elected; highest votes for Benesh (280.3M) and Lucas (280.1M); lowest for Lockett (170.0M).
CME Group enters $2.25B credit facility maturing 2030, amends $7B clearing facility
New $2.25B multi-currency revolving credit facility matures April 23, 2030; can be increased to $3.25B.
CME Group Q1 2025 earnings released; specifics not included in 8-K
CME Group disclosed Q1 2025 financial results via press release on April 23, 2025, but no revenue or EPS figures are available in this filing.
CME Group and S&P Global sell OSTTRA joint venture to KKR for $3.1B
Total enterprise value of $3.1 billion; proceeds split 50/50 between CME and S&P Global.
CME Group issues $750M 4.400% Notes due 2030 to refinance 2025 notes
Issued $750M aggregate principal of 4.400% Notes due March 15, 2030 at 99.573% of par.
CME Group issues $750M of 4.400% Notes due 2030 in public offering
Principal amount $750M at 4.400% interest, maturing 2030.
CME Group reports Q4 2024 financial results; details not available in filing text
Press release for quarter ended December 31, 2024 furnished as Exhibit 99.1.
CME Group updates Clearing House collateral fees and client pricing
Changes communicated via Advisory Notice 24-383 and Special Executive Report 9482.
CME Group declares $2.1B annual variable dividend ($5.80/share) and $3B share repurchase program
Annual variable dividend of $5.80 per share ($2.1B total) payable Jan 16, 2025 to holders of record Dec 27, 2024.
CME Group extends CEO Terry Duffy's contract to Dec 2026; appoints new President/CFO and COO
Chairman and CEO Terry Duffy's employment extended through December 31, 2026; no changes to base salary, bonus, or LTI target.
CME Group reports Q3 results; press release not fully extracted
Filing indicates Q3 2024 earnings released; press release text not included in this excerpt.
CME Group announces Q2 2024 earnings; specific figures not provided in filing text
Filed Form 8-K on July 24, 2024 with Item 2.02 for Q2 2024 results.
Mike Dennis joins as Senior Managing Director, Global Head of Fixed Income, reporting to CEO Terry Duffy.
CME Group annual meeting: all equity directors elected, Class B quorum not met
All 17 Equity Directors elected; Phyllis Lockett received 103.8M against, highest dissent.
CME subsidiary amends credit facility to $7B, eligible to increase to $10B
Amendment No. 8 to existing 364-day multi-currency credit facility executed on April 24, 2024.
CME Group reports Q1 2024 results; specific numbers unavailable from filing text
CME Group filed Q1 2024 earnings results on April 24, 2024 via Form 8-K.
CME Group amends omnibus stock plan to add double-trigger change-of-control vesting
Compensation Committee approved Fourth Amended and Restated Omnibus Stock Plan effective March 1, 2024.
CME Group files Q4 2023 earnings press release; no specific results in this excerpt
Press release dated Feb 14, 2024 reports financial results for quarter ended Dec 31, 2023.
CME Group extends CEO Terrence Duffy's contract to Dec 31, 2025 with same terms
CEO Duffy's term extended to Dec 31, 2025; base salary unchanged at $2M, bonus target 200% of base, equity target 600% of base.
CME Group communicates pricing changes in SER 9295, effective Feb 1, 2024
CME Group issued Special Executive Report 9295 on Nov 29, 2023, detailing pricing changes to clients.
CME Group enters retirement agreement with former CFO Pietrowicz, effective Dec 31, 2023
John Pietrowicz to retire as Special Advisor on Dec 31, 2023; will receive base salary through date.
CME Group Q3 2023 earnings released; data missing from filed exhibit
Exhibit 99.1 press release dated Oct 25, 2023, is referenced but not included in the provided text.
CME Clearing House updates collateral fee schedule effective Jan 2, 2024
Changes to collateral fee schedule communicated via Advisory Notice 23-290 to Clearing Member Firms.
CME Group releases Q2 2023 earnings press release; no financial figures provided in 8-K excerpt.
CME Group filed an 8-K on July 26, 2023, attaching a press release with Q2 2023 financial results.
CME shareholders reject executive compensation in say-on-pay vote at 2023 annual meeting
Advisory vote on executive compensation failed: 192,824,961 against vs 91,525,185 for.
CME Group renews $7B backstop credit facility for clearing subsidiary
Amendments to 364-day multi-currency secured credit facility for Chicago Mercantile Exchange Inc.
CME Group reports Q1 2023 results on April 26, 2023; details not available in filing excerpt
Press release furnished as Exhibit 99.1 but not included in the provided text.
Sean Tully, Senior Managing Director Global Head Rates & OTC Products, will retire on June 2, 2023.
CME Group finalizes CFO retirement, new severance plan for U.S. employees
John W. Pietrowicz to retire as CFO effective 4/1/23; stays as Special Advisor through 12/31/23 with $600K base salary, 100% bonus target, 300% equity target.
CME Group CFO John Pietrowicz to retire April 1; Lynne Fitzpatrick named successor
John W. Pietrowicz retires as CFO effective April 1, 2023; will serve as Special Advisor until Dec 31, 2023.
CME Group announces Q4 2022 results; specific figures not available in filing
Press release attached reporting financial results for quarter ended Dec 31, 2022.
Board approved and adopted Amended Bylaws effective Dec 7, 2022, addressing Universal Proxy Rule 14a-19.
CME Group announces pricing changes effective February 1, 2023 via SER 9098
Pricing changes communicated to clients on November 29, 2022 via Special Executive Report 9098.
CME Group reports Q3 2022 financial results; press release attached
Press release as Exhibit 99.1 covers Q3 2022 results for the period ended September 30, 2022.
CME Group reports Q2 2022 results; press release text not available for extraction
Filing under Item 2.02 indicates financial results for quarter ended June 30, 2022 were released.
CME Group say-on-pay fails; all equity directors re-elected at 2022 annual meeting
Shareholders rejected advisory vote on executive compensation: 211M against vs 64M for (76.7% against).
CME subsidiary amends $7B multi-currency credit facility; can be upsized to $10B
Chicago Mercantile Exchange entered Amendment No. 6 to its 364-day secured revolving credit facility.
Ms. Fitzpatrick will continue to serve as the Company’s President and Chief Financial Officer through the Transition Date and will then assume the role of Chief Executive Officer and be appointed to the Board and its Executive Committee on the Transition Date.
Lynne C. Fitzpatrick, the Company’s current President and Chief Financial Officer, will succeed Mr. Duffy as the Company’s Chief Executive Officer
Terrence A. Duffy, the Company’s current Chairman and Chief Executive Officer, will become the Company’s Executive Chairman
the Company announced that Ms. Julie Holzrichter has decided to step down from her role as Chief Operating Officer, a position she held since 2014.
Ms. Suzanne Sprague who has served as our Senior Managing Director & Global Head of Clearing and Post-Trade Services since February 2022 has also assumed the role of Chief Operating Officer.
Ms. Lynne Fitzpatrick has been promoted to President and Chief Financial Officer.
on July 8, 2024, Mr. Dennis notified the Company of his intent to retire from the Company’s Board of Directors, effective immediately.
Michael G. Dennis will be joining CME Group Inc. (the “CME Group” or the “Company”) as of August 5, 2024 in the role of Senior Managing Director Global Head, Fixed Income.
Under the terms of the Retirement Agreement, Mr. Pietrowicz will retire from the Company on December 31, 2023 (the “Retirement Date”).
On March 30, 2023, CME Group Inc. (“CME Group” or the “Company”) announced that Sean Tully, Senior Managing Director Global Head Rates & OTC Products, will retire from the Company as of June 2, 2023.
On February 28, 2023, CME Group Inc. (“CME Group” or the “Company”) filed a Current Report on Form 8-K announcing that John W. Pietrowicz will retire from his position as Chief Financial Officer and Ms. Fitzpatrick will assume the role effective as of April 1, 2023.
On February 28, 2023, CME Group Inc. (“CME Group” or the “Company”) filed a Current Report on Form 8-K announcing that John W. Pietrowicz will retire from his position as Chief Financial Officer and Ms. Fitzpatrick will assume the role effective as of April 1, 2023.
Max materiality 0.85 · Median 0.38 · Most common event earnings